Evotec AG

EVO Healthcare Drug Manufacturers Specialty & Generic

Evotec AG’s revenue for fiscal 2025 (year ended December 2025) was $892.0 million, up 3.43% from fiscal 2024.

Revenue
−13.0%
EPS
−328.9%
Free cash flow
−9,727.2%
Total debt
+5.48%

Quarter to June 2026, against a year earlier

1.76 0.19 +12.10%
Market cap
$630.4M
P/E
0.0×
Fwd P/E
−2.2×
Dividend yield
—
F-score
5/9
Altman Z
0.64
Beneish M
−2.62
Dividend safety
n/a

Evotec AG (EVO) P/E ratio

Alert me on P/E ratio

Evotec AG has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 1,286× (February 2021) — the current reading is the lowest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 30.9× (97.05%)
FY2020 1,049× 1,027.72%
FY2019 93.0× 205.74%
FY2018 30.4× (66.58%)
FY2017 91.0× 157.13%
FY2016 35.4× 17.45%

Quarterly newest first

Period P/E ratio Change
Mar 2026 0.0× —
Dec 2025 0.0× —
Sep 2025 0.0× —
Jun 2025 0.0× —
39 more quarters

Against its own ten years

Low 0.0× High 1,286×
Ten-year median 35.0×
Current reading's percentile 39

P/E ratio against peers

Company P/E ratio
TKNO Alpha Teknova, Inc. compare n/m
AQST Aquestive Therapeutics, Inc. compare n/m
ACB Aurora Cannabis Inc. compare n/m
EVO Evotec AG n/m
TLRY Tilray Brands, Inc. compare n/m
EOLS Evolus, Inc. compare n/m
IRWD Ironwood Pharmaceuticals, Inc. compare 4.3×
KMDA Kamada Ltd. compare 18.1×
COLL Collegium Pharmaceutical, Inc. compare 20.5×
Drug Manufacturers Specialty & Generic industry median 20.5×
Healthcare sector median 25.2×
Market median 17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on EVO